Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.99 Million EUR | -71.04% |
| 2022 | -10.5 Million EUR | -1.55% |
| 2021 | -10.34 Million EUR | -85.55% |
| 2020 | -5.57 Million EUR | -5.75% |
| 2019 | -5.27 Million EUR | 3.57% |
| 2018 | -5.46 Million EUR | -41.46% |
| 2017 | -3.86 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -3.5 Million EUR | 0.0% |
| 2023 Q3 | -4.41 Million EUR | -25.86% |
| 2023 Q1 | -3.5 Million EUR | -4.87% |
| 2023 FY | -17.97 Million EUR | -71.04% |
| 2023 Q4 | -4.44 Million EUR | -0.71% |
| 2022 Q2 | -5.01 Million EUR | -108.14% |
| 2022 FY | -10.5 Million EUR | -1.55% |
| 2022 Q4 | -3.34 Million EUR | 0.0% |
| 2022 Q3 | -3.34 Million EUR | 33.29% |
| 2022 Q1 | -2.4 Million EUR | 7.17% |
| 2021 FY | -10.34 Million EUR | -85.55% |
| 2021 Q4 | -2.59 Million EUR | 37.17% |
| 2021 Q3 | -4.13 Million EUR | -74.11% |
| 2021 Q2 | -2.37 Million EUR | -129.73% |
| 2021 Q1 | -1.03 Million EUR | -43.1% |
| 2020 Q2 | -2.36 Million EUR | -87.42% |
| 2020 FY | -5.57 Million EUR | -5.75% |
| 2020 Q4 | -721.5 Thousand EUR | 0.0% |
| 2020 Q1 | -1.26 Million EUR | -141.68% |
| 2020 Q3 | -721.5 Thousand EUR | 69.54% |
| 2019 Q2 | -463 Thousand EUR | 17.62% |
| 2019 Q3 | -523 Thousand EUR | -12.96% |
| 2019 Q1 | -562 Thousand EUR | 0.0% |
| 2019 FY | -5.27 Million EUR | 3.57% |
| 2019 Q4 | -523 Thousand EUR | 0.0% |
| 2018 FY | -5.46 Million EUR | -41.46% |
| 2017 FY | -3.86 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -368.728% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 87.444% |
| Adocia SA | -17.62 Million EUR | 9.244% |
| Aelis Farma SA | -6.46 Million EUR | -147.531% |
| Biophytis S.A. | -14.33 Million EUR | -11.582% |
| Advicenne S.A. | -6.45 Million EUR | -147.685% |
| genOway Société anonyme | 2.06 Million EUR | 874.368% |
| IntegraGen SA | -183.77 Thousand EUR | -8602.726% |
| Medesis Pharma S.A. | -4.22 Million EUR | -278.144% |
| Neovacs S.A. | -6.9 Million EUR | -131.529% |
| NFL Biosciences SA | -4.43 Million EUR | -260.982% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -1955.03% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -409.777% |
| Sensorion SA | -22.31 Million EUR | 28.317% |
| Theranexus Société Anonyme | -7.64 Million EUR | -109.232% |
| TME Pharma N.V. | -5.62 Million EUR | -184.371% |
| Valbiotis SA | -7.16 Million EUR | -123.366% |
| TheraVet SA | -2.17 Million EUR | -635.273% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 21.17% |
| argenx SE | -417.15 Million EUR | 96.166% |
| BioSenic S.A. | -7.04 Million EUR | -127.173% |
| Celyad Oncology SA | -8.45 Million EUR | -89.11% |
| DBV Technologies S.A. | -85.24 Million EUR | 81.239% |
| Galapagos NV | -88.26 Million EUR | 81.88% |
| Genfit S.A. | -26.58 Million EUR | 39.831% |
| GeNeuro SA | -14.35 Million EUR | -11.393% |
| Innate Pharma S.A. | -12.66 Million EUR | -26.237% |
| Inventiva S.A. | -102.7 Million EUR | 84.429% |
| MaaT Pharma SA | -19.94 Million EUR | 19.806% |
| MedinCell S.A. | -20.97 Million EUR | 23.759% |
| Nanobiotix S.A. | -26.77 Million EUR | 40.278% |
| Onward Medical N.V. | -35.46 Million EUR | 54.902% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -251.557% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 30.423% |
| Oxurion NV | -12.11 Million EUR | -32.064% |
| Pharming Group N.V. | -4.87 Million EUR | -227.756% |
| Poxel S.A. | -28.76 Million EUR | 44.399% |
| GenSight Biologics S.A. | -29.69 Million EUR | 46.144% |
| Transgene SA | -30.01 Million EUR | 46.711% |
| Financière de Tubize SA | -2.14 Million EUR | -645.951% |
| UCB SA | 604 Million EUR | 102.648% |
| Valneva SE | -82.08 Million EUR | 80.517% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 44.54% |